BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy.  The company launched in August with...
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from...
BioCentury | Mar 17, 2020
Product Development

Phase II data bring Blueprint closer to major market expansion for Ayvakit

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

Merck, Prokaryotics, Princeton ID new class of antibiotic Merck & Co. Inc. (NYSE:MRK), Prokaryotics Inc. and Princeton University researchers reported in a Proceedings of the National Academy of Sciences paper the identification of MRL-494, a...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Aug 9, 2019
Company News

Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos’ momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors...
BioCentury | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Mouse studies suggest inhibiting CMA1 could help treat Japanese encephalitis (JE). In mice non-lethally infected with JE virus, serum levels of a mouse homolog of CMA1 were higher after infection with JE virus...
Items per page:
1 - 10 of 238